Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + vinblastine + doxorubicin + gemcitabine
- Development stage
- Unknown
- Lead developer
- German Hodgkin Study Group
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
PVAG is a combination chemotherapy regimen consisting of prednisone, vinblastine, doxorubicin (Adriamycin), and gemcitabine, specifically developed by the German Hodgkin Study Group (GHSG) and the University of Cologne for the treatment of elderly patients (aged 60-75) with advanced-stage or early unfavorable Hodgkin's lymphoma. The regimen was designed to mitigate the high toxicity associated with standard treatments like BEACOPP or ABVD in older populations while maintaining therapeutic efficacy. Gemcitabine, a nucleoside analog, serves as a key component by inhibiting ribonucleotide reductase and competing with dCTP for incorporation into DNA, leading to chain termination. Doxorubicin acts via DNA intercalation and topoisomerase II inhibition, vinblastine disrupts microtubule formation, and prednisone provides lymphocytolytic effects through glucocorticoid receptor activation.
- Other names
- PVAG regimenPVAG protocolgemcitabine + doxorubicin + vinblastine + prednisone
02
Targets
GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on prednisone + vinblastine + doxorubicin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + vinblastine + doxorubicin + gemcitabine.